´╗┐

Application Process

 

The ECA3 encourages clinical, health services and population health research in the field of atrial fibrillation, syncope and prevention of sudden cardiac death.

The ECA3 award application process closes March 31, 2019 at 23:59.

Please review the ECA3 Policies and Administration Information to ensure that all submission criteria are met.

 

Start your submission now!


Eligibility

To be eligible, applicants must:

  • Be a CCS member and a CANet member;
  • For more information about CCS Membership, visit the CCS website.
  • For more information about CANet Membership, visit the CANet website.
  • The Principle Investigator MUST be an Early Career Investigator, that is a researcher who has held a full time research appointment for a period of no longer than 7 years as of the competition deadline;
  • Hold an MD, and/or PhD and/or PharmD, or equivalent degree;
  • Be a Canadian citizen or landed immigrant with permanent residence in Canada;
  • Proposals that are part of a larger research project must clearly identify the portion of the project that would be funded in its entirety by this award;
  • Not have received funding from another organization (e.g., academic/ research institution, federal or provincial government funding agency, charity or NGO, pharmaceutical company, other research funder) for the proposal being submitted;
  • Not involve a drug and/or medical device supply from any industry company.

Note: The CCS ECA3 funds clinical, health services/systems, and population health research (see CIHR definitions for Themes II-IV research). Proposals for basic biomedical (Theme I) research will not be considered in this round.

 

Eligible Areas of Research*

The following are examples of research areas supported by the ECA3:

  • Clinical research involving humans and small phase IV studies
  • Outcomes/epidemiological research (e.g., structured surveys, pharmacoeconomics, disease management initiatives, program evaluations)

*Any trial involving humans must be conducted in line with ICH guidelines and Canadian regulations (Health Canada).

 

Ineligible Areas of Research

The following are examples of research areas that are NOT ELIGIBLE for the CCS ECA3:

  • Basic science (animal model, in-vivo / in-vitro)
  • Proof of harm or otherwise highly invasive studies (unethical)
  • Repeat of existing studies (lack of innovation)

 

Application Submission and Award Notification

  • Applications to the 2019 ECA3 must be submitted online by March 31, 2019, 11:59
  • Awardees will be notified and awards will be announced by June 30, 2019.

 

About Funding

Four to six (4-6) awards totaling up to $600,000 (each individual award can be up to $150,000) will be awarded based on an independent peer review process. Funded ECA3 research must be completed within 36 months from the start of funding.

Additional budget information:

  • The ECA3 supports only the direct costs of research. No funding is to be used for indirect costs which cannot be directly associated with the proposed research.
  • ECA3 budgets must not include salary support for principal or co-investigators. Salary support for students, technicians, nurses or support staff can be part of the budget request, but must not exceed 50% of the total requested budget.
  • Budgets may include up to $5,000 for travel to present related work. Awardees are expected to attend the annual Canadian Cardiovascular Congress. These costs shall be covered by the budgeted travel amount.
  • Award funds cannot be used for the purchase of major equipment. Minor pieces of equipment can be part of the budget request, but must not exceed 25% of the total grant request.

 

About the Review Process

  • Peer review of all eligible applications will be conducted by a scientific review committee comprised of CCS and CANet members.
  • Reviewers are members of the Canadian medical and scientific community, selected for their expertise in cardiac arrhythmias.
  • All applications will be pre-screened for eligibility. Applications which are late, incomplete, and/or do not meet the basic eligibility criteria will be not be considered for review.
  • All eligible proposals will be reviewed by at least two members of the peer review committee. All applicants will receive feedback from reviewers. All applicants will receive notification of funding/non-funding and awards will be announced by June 30.
  • All ECA3 awardees are expected to attend the Canadian Cardiovascular Congress. The CCS will liaise with awardees about participation in recognition events. The award travel budget may be used to cover awardee travel, accommodation and CCC registration.

 

Application Forms and CCS Research Funding Information

Please review the ECA3 Guidelines and CCS Research Funding Information to ensure that all submission criteria are met.

Supported by:

The Canadian Cardiovascular Society, the Cardiac Arrhythmia Network of Canada, and the Bristol-Myers Squibb/Pfizer Alliance are proud to support the Early Career Atrial Fibrillation & Arrhythmia Award (ECA3), an important initiative to support atrial fibrillation and arrhythmia research in Canada. With this award, we hope to further arrhythmia research to improve the lives of Canadians who are affected by these conditions, and their families.

     
     
ccs logo 
 
 logo canet cmyk

Bristol Myers Squibb Pfizer Logo transparent background